Content deleted Content added
SimLibrarian (talk | contribs) rm number of employees due to crowdsourced source now showing a vague range (1,000-5,000), rm bare URL flag, changed curly to straight punctuation (MOS:CURLY), other style fixes | Dilettante (talk | contribs) Tags: Mobile edit Mobile web edit Advanced mobile edit | ||
Line 41: In June 2018, Roche announced it would acquire Foundation Medicine.<ref>{{cite journal | first1 = Michael | last1 = Shields | first2 = Ben | last2 = Hirschler | name-list-style = vanc | title = Roche pays $2.4 billion for rest of cancer expert Foundation Medicine| url = https://uk.reuters.com/article/us-roche-hldg-m-a-fmi/roche-pays-2-4-billion-for-rest-of-cancer-expert-foundation-medicine-idUKKBN1JF0F3 | date = 19 June 2018 | journal = Reuters }}</ref> [[Guardant Health]] sued Foundation Medicine over [[patent]]s in 2019–2020.<ref>{{cite web |last1=Han |first1=Andrew P. |title=Guardant Health CEO Deleted Email Evidence After Lawsuit Deposition |url=https://www.genomeweb.com/cancer/guardant-health-ceo-deleted-email-evidence-after-lawsuit-deposition#.Yxep4i-B2Rs |website=[[GenomeWeb]] |access-date=September 6, 2022 |date=January 6, 2020}}</ref><ref>{{cite journal |last1=Leuty |first1=Ron |title=Showdown over 'liquid biopsy' patents lands two cancer test players in court again |journal=San Francisco Business Times |date=November 24, 2020 |url=https://www.bizjournals.com/sanfrancisco/news/2020/11/24/cancer-guardant-health-foundation-medicine-roche.html |access-date=September 1, 2022}}</ref> In 2021, Guardant Health licensed [[intellectual property]] to Foundation Medicine for $25 million in a [[Settlement (litigation)|settlement]].<ref>{{cite web |title=Guardant Health to License IP to Foundation Medicine for $25M, Royalties Under Settlement Agreement |url=https://www.genomeweb.com/business-news/guardant-health-license-ip-foundation-medicine-25m-royalties-under-settlement#.Yxeq_i-B2Rs |website=GenomeWeb |access-date=September 6, 2022 |date=May 21, 2021}}</ref> Foundation Medicine is now a subsidiary of Roche and It operates independently.<ref>{{Cite web|url=https://www.roche.com/media/releases/med-cor-2018-06-19.htm|title = Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology}}</ref> | |||